[ [ [[' the 28-year-old neighborhood watchman who shot and killed', 4]], ’28924649′, ’0′ ], [ [['because I know God protects me', 14], ['Brian Snow was at a nearby credit union', 5]], ’28811216′, ’0′ ], [ [['The state news agency RIA-Novosti quoted Rosaviatsiya', 6]], ’28805461′, ’0′ ], [ [['measure all but certain to fail in the face of bipartisan', 4]], ’28771014′, ’0′ ], [ [['matter what you do in this case', 5]], ’28759848′, ’0′ ], [ [['presume laws are constitutional', 7]], ’28747556′, ’0′ ], [ [['has destroyed 15 to 25 houses', 7]], ’28744868′, ’0′ ], [ [['short answer is yes', 7]], ’28746030′, ’0′ ], [ [['opportunity to tell the real story', 7]], ’28731764′, ’0′ ], [ [['entirely respectable way to put off the searing constitutional controversy', 7]], ’28723797′, ’0′ ], [ [['point of my campaign is that big ideas matter', 9]], ’28712293′, ’0′ ], [ [['As the standoff dragged into a second day', 7]], ’28687424′, ’0′ ], [ [['French police stepped up the search', 17]], ’28667224′, ’0′ ], [ [['Seeking to elevate his candidacy back to a general', 8]], ’28660934′, ’0′ ], [ [['The tragic story of Trayvon Martin', 4]], ’28647343′, ’0′ ], [ [['Karzai will get a chance soon to express', 8]], ’28630306′, ’0′ ], [ [['powerful storms stretching', 8]], ’28493546′, ’0′ ], [ [['basic norm that death is private', 6]], ’28413590′, ’0′ ], [ [['songwriter also saw a surge in sales for her debut album', 6]], ’28413590′, ’1′, ‘Watch music videos from Whitney Houston ‘, ‘on Yahoo! Music’, ‘http://music.yahoo.com’ ], [ [['keyword', 99999999999999999999999]], ‘videoID’, ’1′, ‘overwrite-pre-description’, ‘overwrite-link-string’, ‘overwrite-link-url’ ] ]

earthquake think like a man world peace world peace lakers colorectal cancer metta kashi

Daniel Radcliffe
Photo: Getty Images

What do Don Draper and Harry Potter have in common? They’re both about to become doctors.

The Internet was buzzing earlier this month when rumors popped up that actors Jon Hamm and Daniel Radcliffe were set to play the older and younger version of a Russian doctor in a four-part British miniseries set during the end of World War I. On Friday (May 18), Sky Arts, the network set to air the series in 2013, confirmed that we’ll indeed get to see Dr. HammRad in action. “A Young Doctor’s Notebook” is a dramedy based on a short-story collection by Mikhail Bulgakov, a Russian writer and playwright.

“I have been an obsessive Bulgakov reader for a couple of years now,” Radcliffe said in a statement about the television program. “So when the opportunity to become involved in this project came up, I could barely contain my excitement. The book is funny, grotesque and heartfelt in equal measure and I look forward to working with a great group of people to help bring it to life.”

Hamm agreed with his new co-star’s enthusiasm, saying, “I am thrilled to get the opportunity to work on such rich source material with such fantastically talented people whose work I greatly respect.”

The actors will play the same character in different time periods, occasionally interacting with each other. The original rumors were reported by The Sun, which said the show “will incorporate dark humour as the doctor attempts to overcome self-doubts about his competence.”

When MTV News spoke to Radcliffe last summer, he explained he’s attracted to darker tales because he finds them much more interesting.

“I don’t want to make a boring love story about two people who meet and then are happy. That’s boring, and that doesn’t exist,” Radcliffe said. “I also do like playing slightly disenfranchised characters like Arthur is in ‘The Woman in Black.’ He’s someone who’s grieving and whose grief has put him to the edge of madness and also has sort of made him ostracize himself from society. I guess I like the dark stuff. I find it more interesting.”

Hamm said producer Clelia Mountford and production company Big Talk have been “unabashedly” advocating for the series. “I share their great enthusiasm for bringing something original, dark, funny and moving to light,” the actor said. “Also, I have been watching ‘Bridget Jones’s Diary’ on infinite loop, and I think I’ve finally got this accent thing sorted…”

For breaking news, celebrity columns, humor and more — updated around the clock — visit MTVMoviesBlog.com.

chicago weather forecast narcolepsy narcolepsy weather st louis faceoff kings island red hot chili peppers tour

trisomy 18 ozzie guillen ozzie guillen buster posey eric holder eric holder carole king

By Roland Jones

Excitement is mounting for Facebook?s expected debut on financial markets Friday. So if you?re an individual investor, can you get a piece of the action, and should you?

The first thing to remember about IPOs is that they are not normally geared toward individual investors. Underwriting banks typically allocate IPO shares to their best clients, which include hedge funds, wealthy individuals and large institutional investors. These investors will get the right to buy a certain number of shares at the offering price, which is expected to be announced Thursday afternoon. Facebook estimates the offering price will be in the range of $28 to $35 a share.

Some smaller retail investors may get a few shares allocated, especially if they have a good relationship with a broker for one of the dozens of underwriting firms handling the transaction.

If you have not already been in touch with your broker, however, it is too late to even try get in at the offering price. The deadline to express interest was Tuesday afternoon at brokerages we checked with, and the deal reportedly is oversubscribed.

Your only option is to buy shares after they begin trading on the Nasdaq stock market, when the price will be set by the law of supply and demand.

?This is not a strategy for the faint of heart,??said Hugh Johnson, chief investment officer of Hugh Johnson Advisors in Albany, N.Y.?Intense?interest in Facebook?s offering is likely to drive the price up sharply as soon as trading begins, meaning the first public trade could be well above the offering price.

In an example of the type of pressure investors could face, LinkedIn, another social media company, went public almost exactly a year ago at $45 a share and closed at $94 on a volatile first day of trading that saw its shares top $122 at one point.

That means investors lucky enough to get in at the offering price were able to book an immediate paper profit of more than 100 percent or?”flip” shares and cash in. Other investors paid as much as $122 a share for LinkedIn that day and were left with paper losses. (LinkedIn shares currently trade for about $113.)?

Facebook could easily see a similar first-day trajectory, but it is impossible to know. Online investors who place a general order for Facebook stock will get shares at whatever price happens to be prevailing at the moment.

?Is it a sound investment for a sensible portfolio? No,” said Johnson. “Is it a worthwhile speculative investment? Sure, but you have to be fully prepared for something that could be a very emotional event. And I have the sense that [the IPO price] could be very overvalued.?

One good piece of news about Facebook?s IPO is there are plenty of shares up for grabs.

In a sign of intense investor interest, Facebook said early investors in the company will be selling more of their shares in the IPO, bringing the total number of shares available to as many as 421.2 million, up from a previous maximum of 337.4 million.

The news came a day after Facebook raised the expected price range for the stock to a range of $34 to $38 per share, up from its previous range of $28 to $35.

Still, despite the increased number of shares on offer, the hype and interest surrounding Facebook?s IPO are precisely why investors should be cautious about investing in the company, said Professor Anant Sundaram of the Tuck School of Business at Dartmouth.

?My concern is the market is pricing [Facebook] to perfection ? and the kind of fundamentals that are premised in that valuation, growth and revenues and cash flows, are simply astronomical,? he told CNBC Wednesday. ?Now it?s possible they could achieve that, but I think the probability is low.?

Sundaram also says the fact that founder Mark Zuckerberg will control more than 50 percent of the company?s voting rights after it goes public is ?very, very troubling.?

While a handful of new technology companies, such as Google, have thrived under the tight control of their founders, the stock ownership structure at Facebook limits the ability of shareholders to take action if things go wrong.?He?said evidence shows tightly controlled companies are more likely to wasteful acquisitions, overpay employees and spend unnecessarily on capital expenditures.

Other technology companies, such as Microsoft and Apple, have fared well without that sort of governance structure, Sundaram said.?

?Basically, as investors we are being asked to liquefy and validate a lot of insider wealth, and being told to sit and zip your lips in the peanut gallery,? he said.

While Facebook is expected to get a big opening-day ?pop,? Kathleen Shelton Smith, co-founder and chairman of IPO research company Renaissance Capital says it?s more important to track what Facebook?s stock price will be a week or a month after its initial trading day.

?For an IPO to work it has to trade higher over time after the initial trading day, and not all of them do,? said Smith. ?So the challenge for the underwriters is to price the IPO where it can move higher over time.?

CNBC’s Kayla Tausche reports Facebook’s IPO is expected to be priced in the $34 to $38 range after the market closes today.

?The question is, over time will the company deliver the kind of performance that justifies its price? Every investor studying this company wants to work that out.?

For individual investors, it is worth remembering that Facebook shares will be available on Nasdaq for the foreseeable future. Would-be investors can wait a day or two and buy shares when the price is less volatile.

For investors interested in IPOs, but unable to purchase them directly, Smith suggests investing in a mutual fund that track the IPO market, such as the Direxion Long/Short Global IPO Fund (ticker:?DXIIX) or the Renaissance Global IPO Plus Aftermarket Fund (ticker:?IPOSX).

Investing in these funds might even be a smarter play than buying Facebook shares directly. Sundaram said there are many reasons to expect Facebook shares to fall after their opening day.

He pointed to similar technology companies such as?Zynga, which have seen their share prices fall after the expiration of “lockups” that prevent company insiders and major investors from selling for at least 90 days after a stock is first publicly traded.

If Facebook shares manage to hold their value??that would be a remarkable achievement in my book,? he said.

Related:

Mr. IPO:?Facebook could be a dangerous bet

Goldman could make $1.09 billion in Facebook IPO

{“contentId”:”11733892″,”totalVotes”:”573″}

Will shares of Facebook be a good investment?

incendiary floyd mayweather winter solstice x factor finale pro bowl voting kindle fire update college board

belize adele lyrics bruno mars best new artist 2012 grammys foo fighters nikki minaj

By: prnorth87

May 17, 2012 at 6:22 pm

VN:F [1.9.17_1161]

Rating: 5.0/5 (1 vote cast)

BETHESDA, MD, May 17, 2012 ? Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) announced today that it now has 41 clinical trial sites open and recruiting across the United States in its ongoing clinical trial of DCVax?-L immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. This is ahead of the Company?s previous projection of 40 sites by the end of Q2, 2012. The Company plans to continue adding clinical trial sites in the US and Europe, and expects to have at least 60 sites open and enrolling by the end of Q3, 2012.

The Company also announced that the FDA has accepted an amendment of the clinical trial, which does not make any change in the treatment regimen, which leaves all data collected to date intact for use in the trial?s overall results, and which includes the following:

- Designation as a Phase III trial

- Expanded and enhanced statistical endpoint analyses

- Addition of another cohort of patients which can potentially expand the application of DCVax?-L, and which increases the trial to up to 300 patients

- Addition of interim analyses for efficacy

A description of the trial protocol as amended will be available at www.clinicaltrials.gov.

Linda Powers, CEO of Northwest Bio, commented, ?Of course, the evolution of this trial to a Phase III trial is no assurance of the outcome, and more than one Phase III trial can often be required for a product approval unless the clinical results are particularly strong. However, we are pleased to make this transition to Phase III, and believe that the package of amendments further enhances an already strong trial, positioning the Company to realize the potential of the DCVax? technology.?

Ms. Powers added, ?We are excited about the operational progress we have made on multiple fronts, through long periods of work building to these points, as described in our recent announcements. Our lead clinical trial has grown and emerged as a 300-patient, international Phase III trial involving some of the best institutions in the US, UK and Germany. We are also working on several other initiatives, and will provide reports when milestones are reached in those programs.?

For further information about the Company and its programs, please visit the Company?s website at www.nwbio.com.

About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. The Company has a broad platform technology for DCVax? dendritic cell-based vaccines. The Company?s lead clinical trial is a Phase III trial, with up to 300 patients with newly diagnosed GBM for whom surgery is indicated. GBM is the most aggressive and lethal brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I/II trials in multiple other cancers. The Company has also conducted a Phase I/II trial with DCVax? for metastatic ovarian cancer.

Disclaimer
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax? and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as ?expect,? ?believe,? ?intend,? ?plan,? ?continue,? ?may,? ?will,? ?anticipate,? and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company?s ability to raise additional capital, risks related to the Company?s ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company?s products will demonstrate safety and efficacy. Additional information on these and other factors, including Risk Factors, which could affect the Company?s results, is included in its Securities and Exchange Commission (?SEC?) filings. Finally, there may be other factors not mentioned above or included in the Company?s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
Distributed By ShareWellNewswire.com

VN:F [1.9.17_1161]

NORTHWEST BIO PROVIDES UPDATE ON DCVAX?-L BRAIN CANCER TRIAL, 5.0 out of 5 based on 1 rating

Related posts:

1. Shopandbragg.com joins the fight against cancer. When you purchase an item, 2.5% will go to the American Cancer Society. Please join in the fight against cancer.
2. RainyDay Basement Systems to Exhibit at Northwest Washington Fair
3. Mr. Basement Participates in Breast Cancer Charity

Tags: BRAIN CANCER TRIAL, DCVAX

colton bo ryan the last waltz columbine earth day activities mel gibson splunk